CA2496002A1 - Albumin-fused ciliary neurotrophic factor - Google Patents

Albumin-fused ciliary neurotrophic factor Download PDF

Info

Publication number
CA2496002A1
CA2496002A1 CA002496002A CA2496002A CA2496002A1 CA 2496002 A1 CA2496002 A1 CA 2496002A1 CA 002496002 A CA002496002 A CA 002496002A CA 2496002 A CA2496002 A CA 2496002A CA 2496002 A1 CA2496002 A1 CA 2496002A1
Authority
CA
Canada
Prior art keywords
albumin
protein
fused
biologically active
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002496002A
Other languages
English (en)
French (fr)
Inventor
Mathias Juers
Thomas Weimer
Hans-Peter Hauser
Darrell Sleep
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Biopharma DK AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2496002A1 publication Critical patent/CA2496002A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002496002A 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor Abandoned CA2496002A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40183302P 2002-08-07 2002-08-07
US60/401,833 2002-08-07
PCT/EP2003/008710 WO2004015113A2 (en) 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor

Publications (1)

Publication Number Publication Date
CA2496002A1 true CA2496002A1 (en) 2004-02-19

Family

ID=31715745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002496002A Abandoned CA2496002A1 (en) 2002-08-07 2003-08-06 Albumin-fused ciliary neurotrophic factor

Country Status (6)

Country Link
EP (1) EP1529108A2 (https=)
JP (2) JP2005534330A (https=)
KR (1) KR20050065519A (https=)
AU (1) AU2003271043A1 (https=)
CA (1) CA2496002A1 (https=)
WO (1) WO2004015113A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
DK2330200T3 (en) 2004-12-23 2017-07-24 Albumedix As GENE EXPRESSION TECHNIQUE
CN102462662A (zh) * 2010-08-16 2012-05-23 重庆富进生物医药有限公司 脂质体包裹重组人睫状神经营养因子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US6927040B2 (en) * 2000-06-30 2005-08-09 Zymogenetics, Inc. Interferon-like protein Zcyto21

Also Published As

Publication number Publication date
JP2005534330A (ja) 2005-11-17
KR20050065519A (ko) 2005-06-29
JP2010213707A (ja) 2010-09-30
WO2004015113A2 (en) 2004-02-19
WO2004015113A3 (en) 2004-05-06
EP1529108A2 (en) 2005-05-11
AU2003271043A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
US20190085043A1 (en) Fusion proteins for treating a metabolic syndrome
CN102197049B (zh) 胰岛淀粉样多肽衍生物
US20210380654A1 (en) Human fibroblast growth factor 21 (hfgf21) fusion protein, preparation method therefor, and use thereof
US20080293638A1 (en) Albumin-fused ciliary neurotrophic factor
US20160152686A1 (en) Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
KR20140043764A (ko) 폴리펩티드
CN105008395B (zh) 长效单链胰岛素类似物
KR20150131213A (ko) 인슐린-인크레틴 접합체들
AU2003200839A1 (en) Extended glucagon-like peptide-1 analogs
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
Bulaj et al. Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities
EP3285798A2 (en) Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
KR20200024263A (ko) 고혈당증의 치료 및 예방을 위한 펩타이드
WO2018112200A1 (en) Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia
JP2010213707A (ja) アルブミン融合繊毛様神経栄養因子
US11179444B2 (en) Glucagon analogs and methods of use thereof
Sannikova et al. Specific activity of recombinant modified human glucagon-like peptide 1
KR20150110677A (ko) N 말단 절단된 인슐린 유사체
CN109195983B (zh) 胰岛新生多肽和类似物的缀合物及其方法
WO2026039340A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039341A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026039359A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
OA17206A (en) Fusion proteins for treating a metabolic syndrome.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued